Roflumilast foam for hidradenitis suppurativa
Part of Infections, Skin clinical trials.
This study tests if a foam applied to the skin (roflumilast 0.3%) is safe and effective for treating hidradenitis suppurativa (HS). It may help people with mild to moderate HS who haven't had success with other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be at least 18 years old.
- Must have been diagnosed with HS and have had at least 5 typical sores (red bumps, nodules, or abscesses) in skin-fold areas that keep coming back.
- Must be able to apply the foam on your skin without help.
- Must be on a stable dose of any other medications you take for HS for at least 3 months before joining and during the study.
- Women who can get pregnant must have a negative pregnancy test and use birth control during the study.
- Must not be using certain topical treatments (like antibiotics, steroids, or other creams) for at least a week before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether an adapted antibiotic treatment works better than the standard approach to control hidradenitis suppurativa (HS) symptoms and flares. It may help people with stage 2 HS reduce active inflammation and flare-ups.
This study tests a cream called ruxolitinib for people with hidradenitis suppurativa (HS). The goal is to see how much of the cream is absorbed when it's applied to a large area of the body.
This trial tests a new medicine called HB0043 for people with moderate to severe hidradenitis suppurativa (a skin condition causing painful lumps). It aims to see if the drug is safe and helps reduce symptoms.
This trial tests a new medication, SAR445399, for people with moderate to severe hidradenitis suppurativa (HS) who haven't improved with oral antibiotics. It aims to see if the drug safely reduces skin bumps and abscesses.
This study tests a new medicine called LAD191 for people with moderate to severe hidradenitis suppurativa (HS) who haven't been helped enough by antibiotics. Researchers want to see if LAD191 safely reduces painful bumps and tunnels.
This study tracks how secukinumab (a new medication) works for hidradenitis suppurativa—a painful skin condition with recurring boils and abscesses—in real-world patient care in Italy. Researchers want to understand treatment patterns and outcomes to help improve care for this condition.
Hear when a new Hidradenitis Suppurativa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.